128 Spring Street
Building A Suite 510
Lexington, MA 02421
United States
857 285 4140
https://cyteir.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 46
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board | 81.5k | N/D | 1962 |
Dr. Markus F. Renschler M.D. | President, CEO & Director | 718.62k | N/D | 1961 |
Dr. Kevin Mills Ph.D. | Co-Founder | N/D | N/D | N/D |
Mr. David G. Gaiero | CFO & Treasurer | N/D | N/D | 1978 |
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
La calificación ISS Governance QuickScore de Cyteir Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.